Skip to main content
Erschienen in: Indian Journal of Surgery 2/2015

01.04.2015 | Review Article

Ductal Carcinoma In Situ of the Breast

verfasst von: Yash Vaidya, Pradeep Vaidya, Tanvi Vaidya

Erschienen in: Indian Journal of Surgery | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Ductal carcinoma in situ (DCIS) of the breast is a potentially invasive neoplasm. Risk factors include high estrogen states such as use of oral contraceptive (OC) pills, nulliparity, advanced age at first birth, and also family history and genetic mutations. The incidence of this usually clinically silent condition has risen in the past few decades due to widespread screening and diagnostic mammography, with final diagnosis confirmed by biopsy. At present, treatment options include total or simple mastectomy or lumpectomy with radiation. Adjuvant therapy includes antiestrogens like tamoxifen and human epidermal growth factor receptor 2 (HER2) suppression therapy. With the latest advances in chemotherapy and better understanding on the pathogenesis of the lesion, it is anticipated that more effective modalities of treatment may soon be available.
Literatur
1.
Zurück zum Zitat Rosner D, Bedwani RN, Vana J (1980) Noninvasive breast carcinoma. Results of a national survey by the American College of Surgeons. Ann Surg 192:139–147PubMedCentralPubMedCrossRef Rosner D, Bedwani RN, Vana J (1980) Noninvasive breast carcinoma. Results of a national survey by the American College of Surgeons. Ann Surg 192:139–147PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Virnig BA, Tuttle TM, Shamliyan T, Kane RL (2010) Ductal carcinoma in Situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 102(3):170–178PubMedCrossRef Virnig BA, Tuttle TM, Shamliyan T, Kane RL (2010) Ductal carcinoma in Situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 102(3):170–178PubMedCrossRef
3.
Zurück zum Zitat Brinton LA, Sherman ME, Carreon JD, Anderson WF (2008) Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 100:1643–1648PubMedCentralPubMedCrossRef Brinton LA, Sherman ME, Carreon JD, Anderson WF (2008) Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 100:1643–1648PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Ernster VL, Ballard-Barbash R, Barlow WE et al (2002) Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 94:1546–1554PubMedCrossRef Ernster VL, Ballard-Barbash R, Barlow WE et al (2002) Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 94:1546–1554PubMedCrossRef
5.
Zurück zum Zitat May DS, Lee NC, Richardson LC, Giustozzi AG, Bobo JK (2000) Mammography and breast cancer detection by race and Hispanic ethnicity: results from a national program (United States). Cancer Causes Control 11:697–705PubMedCrossRef May DS, Lee NC, Richardson LC, Giustozzi AG, Bobo JK (2000) Mammography and breast cancer detection by race and Hispanic ethnicity: results from a national program (United States). Cancer Causes Control 11:697–705PubMedCrossRef
6.
Zurück zum Zitat Erbas B, Provenzano E, Armes J, Gertig D (2006) The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat 97(2):135–144PubMedCrossRef Erbas B, Provenzano E, Armes J, Gertig D (2006) The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat 97(2):135–144PubMedCrossRef
7.
Zurück zum Zitat O’Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC (1998) Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 90:697–703PubMedCrossRef O’Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC (1998) Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 90:697–703PubMedCrossRef
8.
Zurück zum Zitat Allred DC, Clark GM, Molina R et al (1992) Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23:974–979PubMedCrossRef Allred DC, Clark GM, Molina R et al (1992) Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23:974–979PubMedCrossRef
9.
Zurück zum Zitat Rudas M, Neumayer R, Gnant MFX, Mittelbock M, Jakesz R, Reiner A (1997) p53 Protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer 33:39–44PubMedCrossRef Rudas M, Neumayer R, Gnant MFX, Mittelbock M, Jakesz R, Reiner A (1997) p53 Protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer 33:39–44PubMedCrossRef
10.
Zurück zum Zitat Kerlikowske K, Molinari AM, Gauthier ML (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102(9):627–637PubMedCentralPubMedCrossRef Kerlikowske K, Molinari AM, Gauthier ML (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102(9):627–637PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Radisky DC, Santisteban M, Berman HK et al (2011) p16 INK4a expression and breast cancer risk in women with atypical hyperplasia. Cancer Prev Res 4(12):1953–1960CrossRef Radisky DC, Santisteban M, Berman HK et al (2011) p16 INK4a expression and breast cancer risk in women with atypical hyperplasia. Cancer Prev Res 4(12):1953–1960CrossRef
12.
Zurück zum Zitat Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V (1997) Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst 89:76–82PubMedCrossRef Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V (1997) Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst 89:76–82PubMedCrossRef
13.
Zurück zum Zitat Claus EB, Stowe M, Carter D (2001) Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 93:1811–1817PubMedCrossRef Claus EB, Stowe M, Carter D (2001) Breast carcinoma in situ: risk factors and screening patterns. J Natl Cancer Inst 93:1811–1817PubMedCrossRef
14.
Zurück zum Zitat Trentham-Dietz A, Newcomb PA, Storer BE, Remington PL (2000) Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 9:697–703PubMed Trentham-Dietz A, Newcomb PA, Storer BE, Remington PL (2000) Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 9:697–703PubMed
15.
Zurück zum Zitat Gapstur SM, Morrow M, Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women’s Health Study. JAMA 281(22):2091–2141PubMedCrossRef Gapstur SM, Morrow M, Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women’s Health Study. JAMA 281(22):2091–2141PubMedCrossRef
16.
Zurück zum Zitat Claus EB, Stowe M, Carter D (2003) Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Breast Cancer Res Treat 78:7–15PubMedCrossRef Claus EB, Stowe M, Carter D (2003) Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Breast Cancer Res Treat 78:7–15PubMedCrossRef
17.
Zurück zum Zitat Allred DC (2010) Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr 41:134–138CrossRef Allred DC (2010) Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr 41:134–138CrossRef
18.
Zurück zum Zitat Stomper PC, Connolly JL, Meyer JE, Harris JR (1989) Clinically occult ductal carcinoma in situ detected with mammography: analysis of 100 cases with radiologic-pathologic correlation. Radiology 172:235–241PubMedCrossRef Stomper PC, Connolly JL, Meyer JE, Harris JR (1989) Clinically occult ductal carcinoma in situ detected with mammography: analysis of 100 cases with radiologic-pathologic correlation. Radiology 172:235–241PubMedCrossRef
20.
Zurück zum Zitat Weaver DL, Vacek PM, Skelly JM, Geller BM (2005) Predicting biopsy outcome after mammography: what is the likelihood the patient has invasive or in situ breast cancer? Ann Surg Oncol 12(8):660–673PubMedCrossRef Weaver DL, Vacek PM, Skelly JM, Geller BM (2005) Predicting biopsy outcome after mammography: what is the likelihood the patient has invasive or in situ breast cancer? Ann Surg Oncol 12(8):660–673PubMedCrossRef
21.
Zurück zum Zitat Schouten van der Velden AP, Schlooz-Vries MS, Boetes C, Wobbes T (2009) Magnetic resonance imaging of ductal carcinoma in situ: what is its clinical application? A review. Am J Surg 198(2):262–269PubMedCrossRef Schouten van der Velden AP, Schlooz-Vries MS, Boetes C, Wobbes T (2009) Magnetic resonance imaging of ductal carcinoma in situ: what is its clinical application? A review. Am J Surg 198(2):262–269PubMedCrossRef
22.
Zurück zum Zitat Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R (2000) Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160:953–958PubMedCrossRef Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R (2000) Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160:953–958PubMedCrossRef
23.
Zurück zum Zitat Winchester DJ, Menck HR, Winchester DP (1997) National treatment trends for ductal carcinoma in situ of the breast. Arch Surg 132:660–665PubMedCrossRef Winchester DJ, Menck HR, Winchester DP (1997) National treatment trends for ductal carcinoma in situ of the breast. Arch Surg 132:660–665PubMedCrossRef
24.
Zurück zum Zitat Faverly DR, Burgers L, Bult P, Holland R (1994) Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications. Semin Diagn Pathol 11:193–198PubMed Faverly DR, Burgers L, Bult P, Holland R (1994) Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications. Semin Diagn Pathol 11:193–198PubMed
25.
Zurück zum Zitat Vicini FA, Goldstein NS, Kestin LL (1999) Pathologic and technical considerations in the treatment of ductal carcinoma in situ of the breast with lumpectomy and radiation therapy. Ann Oncol 10(8):883–890PubMedCrossRef Vicini FA, Goldstein NS, Kestin LL (1999) Pathologic and technical considerations in the treatment of ductal carcinoma in situ of the breast with lumpectomy and radiation therapy. Ann Oncol 10(8):883–890PubMedCrossRef
26.
Zurück zum Zitat Silverstein MJ, Rosser RJ, Gierson ED et al (1987) Axillary lymph node dissection for intraductal breast carcinoma—is it indicated? Cancer 59:1819–1824PubMedCrossRef Silverstein MJ, Rosser RJ, Gierson ED et al (1987) Axillary lymph node dissection for intraductal breast carcinoma—is it indicated? Cancer 59:1819–1824PubMedCrossRef
27.
Zurück zum Zitat Wapnir IL, Dignam JJ, Fisher B et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103:478–488PubMedCentralPubMedCrossRef Wapnir IL, Dignam JJ, Fisher B et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103:478–488PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Shah C, McGee M, Wilkinson JB (2012) Clinical outcomes using accelerated partial breast irradiation in patients with ductal carcinoma in situ. Clin Breast Cancer 12:259–263PubMedCrossRef Shah C, McGee M, Wilkinson JB (2012) Clinical outcomes using accelerated partial breast irradiation in patients with ductal carcinoma in situ. Clin Breast Cancer 12:259–263PubMedCrossRef
29.
30.
Zurück zum Zitat Chen L, Mayer JA, Krisko TI et al (2009) Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res 69(23):8853–8861PubMedCentralPubMedCrossRef Chen L, Mayer JA, Krisko TI et al (2009) Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res 69(23):8853–8861PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Li Y, Zhang Y, Hill J et al (2007) The rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor-negative tumors in MMTV-erbB2 mice. Clin Cancer Res 13(20):6224–6231PubMedCrossRef Li Y, Zhang Y, Hill J et al (2007) The rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor-negative tumors in MMTV-erbB2 mice. Clin Cancer Res 13(20):6224–6231PubMedCrossRef
32.
Zurück zum Zitat Crowe DL, Chandraratna RA (2004) A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 6(5):R546–R555PubMedCentralPubMedCrossRef Crowe DL, Chandraratna RA (2004) A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 6(5):R546–R555PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Hartmann LC, Sellers TA, Schaid DJ et al (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93(21):1633–1637PubMedCrossRef Hartmann LC, Sellers TA, Schaid DJ et al (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93(21):1633–1637PubMedCrossRef
34.
Zurück zum Zitat Sakorafas GH, Farley DR (2003) Optimal management of ductal carcinoma in situ of the breast. Surg Oncol 12(4):221–240PubMedCrossRef Sakorafas GH, Farley DR (2003) Optimal management of ductal carcinoma in situ of the breast. Surg Oncol 12(4):221–240PubMedCrossRef
Metadaten
Titel
Ductal Carcinoma In Situ of the Breast
verfasst von
Yash Vaidya
Pradeep Vaidya
Tanvi Vaidya
Publikationsdatum
01.04.2015
Verlag
Springer India
Erschienen in
Indian Journal of Surgery / Ausgabe 2/2015
Print ISSN: 0972-2068
Elektronische ISSN: 0973-9793
DOI
https://doi.org/10.1007/s12262-013-0987-0

Weitere Artikel der Ausgabe 2/2015

Indian Journal of Surgery 2/2015 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.